Literature DB >> 29948950

Resveratrol Induces Brain Resilience Against Alzheimer Neurodegeneration Through Proteostasis Enhancement.

Rubén Corpas1,2, Christian Griñán-Ferré3, Eduard Rodríguez-Farré4,5, Mercè Pallàs3, Coral Sanfeliu6,7.   

Abstract

Resveratrol is a natural compound that mimics the antioxidant and antiaging effects of caloric restriction, mainly mediated through SIRT1, a deacetylase that induces longevity and neuroprotection. We aimed to analyze the effects of resveratrol on the brain status of control non-transgenic (NoTg) and AD transgenic (3xTg-AD) mice to discern the mechanisms involved in a potential inducement of resilience against age-related neurodegeneration and Alzheimer's disease (AD). Mice were fed with a diet supplemented with 100 mg/kg of resveratrol from 2 months of age during 10 months. Resveratrol administration induced complete protection against memory loss and brain pathology in 3xTg-AD mice, and also induced cognitive enhancement in healthy NoTg mice. Resveratrol improved exploration and reduced anxiety in both mouse strains, indicative of well-being. Resveratrol reduced the presence of Aβ and p-tau pathology in the hippocampus of the 3xTg-AD mouse. Proteostasis analysis showed the following in both NoTg and 3xTg-AD mice: (i) increased levels of the amyloid-degrading enzyme neprilysin, (ii) reduction of the amyloidogenic secretase BACE1, and (iii) increase of proteasome protein levels and enhancement of proteasome activity. Resveratrol also increased AMPK protein levels, then upregulating the SIRT1 pathway, as shown by the activation of PGC-1α and CREB in both mice, resulting in further beneficial changes. Our data demonstrated that resveratrol induces cognitive enhancement and neuroprotection against amyloid and tau pathologies. Improvement of proteostasis by resveratrol, in both healthy and AD mice, suggests that it is a mechanism of brain resilience and defense against neurodegeneration caused by the accumulation of aberrant proteins.

Entities:  

Keywords:  3xTg-AD; Neuroprotection; Proteasome; Resveratrol; SIRT1

Mesh:

Substances:

Year:  2018        PMID: 29948950     DOI: 10.1007/s12035-018-1157-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  118 in total

1.  Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

Authors:  Salvatore Oddo; Antonella Caccamo; Jason D Shepherd; M Paul Murphy; Todd E Golde; Rakez Kayed; Raju Metherate; Mark P Mattson; Yama Akbari; Frank M LaFerla
Journal:  Neuron       Date:  2003-07-31       Impact factor: 17.173

Review 2.  A review on Alzheimer's disease pathophysiology and its management: an update.

Authors:  Anil Kumar; Arti Singh
Journal:  Pharmacol Rep       Date:  2014-09-22       Impact factor: 3.024

3.  Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.

Authors:  David J Irwin; Todd J Cohen; Murray Grossman; Steven E Arnold; Sharon X Xie; Virginia M-Y Lee; John Q Trojanowski
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

4.  Resveratrol reduces amyloid-beta (Aβ₁₋₄₂)-induced paralysis through targeting proteostasis in an Alzheimer model of Caenorhabditis elegans.

Authors:  Charlotte Regitz; Elena Fitzenberger; Friederike Luise Mahn; Lisa Marie Dußling; Uwe Wenzel
Journal:  Eur J Nutr       Date:  2015-04-08       Impact factor: 5.614

5.  Melatonin plus physical exercise are highly neuroprotective in the 3xTg-AD mouse.

Authors:  Yoelvis García-Mesa; Lydia Giménez-Llort; Luis C López; Carmen Venegas; Rosa Cristòfol; Germain Escames; Darío Acuña-Castroviejo; Coral Sanfeliu
Journal:  Neurobiol Aging       Date:  2011-12-16       Impact factor: 4.673

6.  Resveratrol is not a direct activator of SIRT1 enzyme activity.

Authors:  Dirk Beher; John Wu; Suzanne Cumine; Ki Won Kim; Shu-Chen Lu; Larissa Atangan; Minghan Wang
Journal:  Chem Biol Drug Des       Date:  2009-10-20       Impact factor: 2.817

7.  Neural stem cells genetically-modified to express neprilysin reduce pathology in Alzheimer transgenic models.

Authors:  Mathew Blurton-Jones; Brian Spencer; Sara Michael; Nicholas A Castello; Andranik A Agazaryan; Joy L Davis; Franz-Josef Müller; Jeanne F Loring; Eliezer Masliah; Frank M LaFerla
Journal:  Stem Cell Res Ther       Date:  2014-04-16       Impact factor: 6.832

Review 8.  Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.

Authors:  Aaron Ciechanover; Yong Tae Kwon
Journal:  Exp Mol Med       Date:  2015-03-13       Impact factor: 8.718

Review 9.  Sirt1 and the Mitochondria.

Authors:  Bor Luen Tang
Journal:  Mol Cells       Date:  2016-02-02       Impact factor: 5.034

Review 10.  Critical review: involvement of endoplasmic reticulum stress in the aetiology of Alzheimer's disease.

Authors:  Shoko Hashimoto; Takaomi C Saido
Journal:  Open Biol       Date:  2018-04       Impact factor: 6.411

View more
  23 in total

1.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

Review 2.  Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.

Authors:  Matthew J Sharman; Giuseppe Verdile; Shanmugam Kirubakaran; Cristina Parenti; Ahilya Singh; Georgina Watt; Tim Karl; Dennis Chang; Chun Guang Li; Gerald Münch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 3.  All roads lead to Rome - a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer's disease.

Authors:  Yi-Yao Liang; Li-Dan Zhang; Xi Luo; Li-Li Wu; Zhao-Wei Chen; Guang-Hao Wei; Kai-Qing Zhang; Ze-An Du; Ren-Zhi Li; Kwok-Fai So; Ang Li
Journal:  Neural Regen Res       Date:  2022-06       Impact factor: 5.135

4.  Effects of resveratrol on alterations in cerebrum energy metabolism caused by metabolites accumulated in type I citrullinemia in rats.

Authors:  Karine Louize Vincenzi; Thayna Patachini Maia; Larissa Delmônego; Aline Barbosa Lima; Luana Carla Pscheidt; Débora Delwing-Dal Magro; Daniela Delwing-de Lima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-11-18       Impact factor: 3.000

5.  Resveratrol Abrogates Hypoxia-Induced Up-Regulation of Exosomal Amyloid-β Partially by Inhibiting CD147.

Authors:  Junchao Xie; Xiaoyan Li; Yuchen Zhou; Jiayan Wu; Yan Tan; Xiaoye Ma; Yichen Zhao; Xueyuan Liu; Yanxin Zhao
Journal:  Neurochem Res       Date:  2019-02-15       Impact factor: 3.996

Review 6.  TTC3-Mediated Protein Quality Control, A Potential Mechanism for Cognitive Impairment.

Authors:  Xu Zhou; Xiongjin Chen; Tingting Hong; Miaoping Zhang; Yujie Cai; Lili Cui
Journal:  Cell Mol Neurobiol       Date:  2021-02-27       Impact factor: 4.231

Review 7.  Modifiable lifestyle factors and cognitive reserve: A systematic review of current evidence.

Authors:  Suhang Song; Yaakov Stern; Yian Gu
Journal:  Ageing Res Rev       Date:  2021-12-21       Impact factor: 11.788

8.  Structural and mechanistic insights into amyloid-β and α-synuclein fibril formation and polyphenol inhibitor efficacy in phospholipid bilayers.

Authors:  Henry M Sanders; Blagojce Jovcevski; Michael T Marty; Tara L Pukala
Journal:  FEBS J       Date:  2021-07-26       Impact factor: 5.542

Review 9.  Some Candidate Drugs for Pharmacotherapy of Alzheimer's Disease.

Authors:  Barbara Miziak; Barbara Błaszczyk; Stanisław J Czuczwar
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-13

10.  A Phenylacetamide Resveratrol Derivative Exerts Inhibitory Effects on Breast Cancer Cell Growth.

Authors:  Adele Chimento; Anna Santarsiero; Domenico Iacopetta; Jessica Ceramella; Arianna De Luca; Vittoria Infantino; Ortensia Ilaria Parisi; Paola Avena; Maria Grazia Bonomo; Carmela Saturnino; Maria Stefania Sinicropi; Vincenzo Pezzi
Journal:  Int J Mol Sci       Date:  2021-05-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.